Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) generates frequent news as it advances antibody-based therapies in immunology, with a particular emphasis on mast cell–driven diseases. Company updates often center on barzolvolimab, a humanized monoclonal antibody targeting the KIT receptor on mast cells, and CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation.
News coverage for Celldex commonly includes clinical trial milestones across multiple indications. For barzolvolimab, the company reports data from Phase 2 studies in chronic spontaneous urticaria (CSU) and chronic inducible urticarias such as cold urticaria (ColdU) and symptomatic dermographism (SD), describing statistically significant improvements in urticaria activity scores, provocation tests and quality-of-life measures, along with favorable safety profiles. Investors and clinicians can also follow announcements about the global Phase 3 EMBARQ-CSU program in CSU and the registrational Phase 3 EMBARQ-ColdU and SD program in ColdU and SD.
Additional Celldex news items highlight expansion of the barzolvolimab program into prurigo nodularis and atopic dermatitis, as well as strategic decisions such as discontinuing development in eosinophilic esophagitis (EoE) after a Phase 2 study showed mast cell depletion without clinical benefit. Updates on CDX-622 provide insight into early-stage safety, pharmacokinetics and pharmacodynamics, including sustained reductions in serum tryptase in healthy volunteers.
Corporate news may feature quarterly financial results, leadership appointments and participation in healthcare and investor conferences. For readers tracking CLDX, this news stream offers a view into Celldex’s progress in mast cell biology, the evolution of its clinical pipeline and key regulatory and financial disclosures. Bookmarking this page allows ongoing access to company-issued press releases and related market-relevant developments.
Celldex Therapeutics (Nasdaq:CLDX) announced its participation in the H.C. Wainwright Global Life Sciences Conference, where a prerecorded fireside chat will be accessible to attendees starting March 9, 2021, at 7:00 a.m. ET. The presentation will be available via webcast on the company's website for fourteen days post-event. Celldex is focused on developing monoclonal and bispecific antibodies aimed at serious diseases, enhancing immune responses, and addressing areas with limited treatment options.
Celldex Therapeutics (Nasdaq: CLDX) announced an expansion of clinical development for CDX-0159 into prurigo nodularis (PN), a chronic skin condition causing intense itch and lesions. The drug, a humanized monoclonal antibody, shows promise by targeting the KIT receptor involved in mast cell activation. CDX-0159 has demonstrated significant plasma tryptase reduction in earlier trials. Celldex aims to initiate the PN study in Q4 2021, responding to a significant unmet medical need as there are currently no FDA-approved therapies for PN, potentially expanding into other itch-driven conditions.
Celldex Therapeutics (Nasdaq: CLDX) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 2:20 p.m. ET. A webcast will be accessible on the 'Events & Presentations' page of the company’s website, with a replay available for 14 days post-event.
Celldex is focused on developing monoclonal and bispecific antibodies to treat serious diseases, aiming to enhance the lives of patients suffering from inflammatory diseases and various cancers.
Celldex Therapeutics, Inc. (Nasdaq:CLDX) has announced the promotion of Freddy A. Jimenez to Senior Vice President and General Counsel, effective January 1, 2021. With over 30 years of experience in the biopharmaceutical industry, Jimenez has significantly contributed to legal strategies supporting the company's R&D and business efforts since joining in 2016. His prior roles include 23 years at Johnson & Johnson, enhancing Celldex's legal compliance and regulatory framework. The leadership change is positioned as crucial for advancing a promising pipeline in 2021.
Celldex Therapeutics (Nasdaq: CLDX) has initiated its open-label clinical trial for CDX-0159, targeting cold contact urticaria and symptomatic dermographism. CDX-0159 is a humanized monoclonal antibody designed to inhibit the KIT receptor, crucial for mast cell activity. The trial aims to assess the drug's safety and clinical efficacy in patients resistant to antihistamines. Preliminary results are expected by Q1 2021. This advancement could address a significant unmet need in a condition affecting 0.5% of the population, positioning CDX-0159 as a potential disease-modifying treatment.
Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on December 2 at 4:20 PM ET. A webcast of the presentation will be available on their website, with a replay accessible for 14 days post-event. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating critical diseases, including inflammatory conditions and various cancers. For detailed information about Celldex's work, visit: www.celldex.com.
Celldex Therapeutics (NASDAQ:CLDX) presented significant updates at the SITC 2020 meeting. Data from the Phase 1 study of CDX-1140, an anti-CD40 monoclonal antibody, highlighted its potential as a best-in-class treatment, showing tumor shrinkage and necrosis in challenging cancer types. The company announced the initiation of expansion cohorts combining CDX-1140 with pembrolizumab and chemotherapy in various cancers. Additionally, CDX-527 and Axl-targeting programs were discussed, indicating ongoing commitment to advancing their innovative therapeutic pipeline.
Celldex Therapeutics (NASDAQ:CLDX) reported Q3 2020 financials, revealing a net loss of $14.2 million, or ($0.36) per share. Revenues increased to $0.7 million, driven by a milestone payment from Rockefeller University. The company initiated two Phase 1b studies for CDX-0159 in chronic spontaneous and inducible urticaria, alongside advancing bispecific candidate CDX-527. Despite cash reserves decreasing to $199.6 million, Celldex maintains that its funding is sufficient to meet operational needs through 2023.
Celldex Therapeutics (Nasdaq:CLDX) has initiated a Phase 1b clinical trial for CDX-0159, targeting chronic spontaneous urticaria (CSU). The trial, which is randomized and double-blind, will assess the safety and efficacy of multiple doses of CDX-0159 in approximately 40 patients with CSU unresponsive to antihistamines. Previous studies demonstrated CDX-0159's favorable safety profile and significant reductions in plasma tryptase levels, indicating its potential as a disease-modifying therapy. Results from the study are anticipated in the latter half of 2021.
Celldex Therapeutics (NASDAQ: CLDX) will participate in two upcoming virtual fireside chats. The first is at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 10:40 AM ET, followed by the HC Wainwright & CO 22nd Annual Global Investment Virtual Conference on September 16, 2020, at 9:00 AM ET. Webcasts of both presentations will be available on the Celldex website, with replays accessible for fourteen days post-event.